Gapping up
In reaction to earnings/guidance:
- GE +7.4%, AUDC +6.3%, LPG +3.7%, ALV +3.7%, HXL +3.1%, PII +3%, RTX +2.8%, GGG +2.5%, STLD +2.4%, IFF +2.3%, UBS +2%, JNJ +1.7%, ADM +1.7%, FUL +1.5%, DQ +1.4%, DHI +1.3%, EPRT +1.2% (guides FY21 AFFO slightly below consensus), SNV +1.1%, NEE +1%, MMM +0.9%, XLNX +0.7%
Other news:
- OSTK +13.7% (announces partnership with Pelion Venture Partners to oversee Medici Ventures' blockchain assets)
- ICLK +10.7% (iClick Interactive Asia Group and Baozun (BZUN) announce equity investment and strategic business cooperation )
- ICFI +10.2% (selected by EPA for Energy Star Services contract)
- HTBX +10.1% (has engaged CRS Crossroads Strategies, a bipartisan government relations firm based in Washington DC, to assist in advancing government collaborations related to COVID-19 and other vaccine programs)
- BB +9.2% (partners with Baidu (BIDU) for next generation autonomous driving technology)
- TLRY +8.8% (has been selected by the French National Agency for the Safety of Medicines and Health Products to supply Good Manufacturing Processes certified medical cannabis products for experimentation in France)
- KLDO +7.1% (Kaleido Biosciences' Katharine Knobil will resign from her position as Chief Medical Officer and Head of Research and Development of the Company, effective as of January 29, 2021)
- CGRO +6.8% (Collective Growth Corporation partners with Macnica, Japan's largest distribution company)
- MYOV +6.7% (Myovant Sciences and Pfizer (PFE) announce "positive" one-year data from Phase 3 SPIRIT extension study of once-daily relugolix combination therapy in women with endometriosis)
- BDGE +6% (to be added to S&P SmallCap 600)
- STAA +5.8% (to be added to S&P MidCap 400)
- PBH +5.2% (to be added to S&P SmallCap 600)
- APO +5.1% (new CEO)
- IAC +3.6% (Vimeo raises $300 mln in primary equity)
- VLDR +3.5% (signs a multi-year sales agreement to provide Puck LITE sensors to Emesent)
- WYND +3.2% (to change name to "Travel + Leisure Co.")
- IMAB +2.8% (IMAB and MOR dose first patient in US Phase 1 study of TJ210/MOR210)
- ABCL +2.5% (announces bamlanivimab administered with etesevimab reduced risk of COVID-19 hospitalizations and death by 70%)
- BZUN +2.1% (iClick Interactive Asia Group and Baozun (BZUN) announce equity investment and strategic business cooperation )
- BP +2% (reduces oil exploration staff to focus more on renewable energy, according to Reuters)
- REGN +1.4% (reports "positive" initial results from ongoing Phase 3 trial of REGEN-COV antibody cocktail as passive COVID-19 vaccine)
- TWTR +1.1% (settles pending shareholder derivative lawsuits)
- LLY +0.9% (reports new data showing treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70%)
Analyst comments:
- DKNG +4.3% (upgraded to Buy from Neutral at Goldman)
- UAA +1.9% (upgraded to Outperform from Market Perform at Cowen)
- PPG +1.7% (upgraded to Buy from Neutral at BofA Securities)
- WES +1.1% (upgraded to Neutral from Underperform at BofA Securities)
- DG +0.8% (upgraded to Buy from Hold at Loop Capital)